Hyper-CVAD Treatment of Adult T-cell Acute Lymphoblastic Leukemia in Sweden.
Hyper-CVAD Treatment of Adult T-cell Acute Lymphoblastic Leukemia in Sweden.
Hyper-CVAD (a chemotherapy regimen) has shown promising results in adult T-cell Acute
 Lymphoblastic Leukemia (T-ALL). Patients with T-ALL diagnosis were reported to the Swedish
 Adult Acute Leukemia Registry between October 2002 and September 2006. Hyper-CVAD was
 recommended to all patients without severe comorbidity. Allogeneic stem cell transplantation
 was recommended for patients with high-risk disease. The aim of this population-based study
 was to assess the efficacy of Hyper-CVAD treatment.
Patients with T-ALL diagnosis were prospectively reported to the Swedish Adult Acute Leukemia
 Registry between October 2002 and September 2006. Missing data were complemented
 retrospectively. Hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, and
 dexamethasone alternating with cycles of high-dose methotrexate and cytarabine) was
 recommended to all patients without severe comorbidity. Allogeneic stem cell transplantation
 (SCT) was recommended for patients with high-risk disease: white blood cell count >100×109/L,
 complete remission (CR) achievement after more than two courses, high minimal residual
 disease level, and relapsed disease (after CR2 achievement). In patients without high-risk
 factors maintenance therapy was given with per oral mercaptopurine and methotrexate for two
 years including reinduction courses: daunorubicine, vincristine and prednisolone every second
 month (1st year) and cytarabine, thioguanine and prednisolone every third month (2nd year).
Inclusion Criteria: all patients with T-ALL diagnosis

 Exclusion Criteria: no